Yahoo May Look to A...
Health Care: Drugs
Teva Pharmaceutical Industries Ltd (TEVA: NYSE)
$40.23 0.27 | 0.68%
05/17/13 - 04:03 PM ET
Company Income Statement
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Sales | 20.32B | 18.31B | 16.12B | 13.90B |
| Cost of Sales | 7.96B | 7.73B | 6.08B | 5.62B |
| Gross Operating Profit | 12.36B | 10.58B | 10.04B | 8.28B |
| Selling, General, and Administrative Expenses | 5.12B | 4.41B | 3.83B | 3.50B |
| Research & Development | 1.36B | 1.10B | 933.00M | 802.00M |
| Operating Income before D & A (EBITDA) | 5.89B | 5.08B | 5.28B | 3.97B |
| Depreciation & Amortization | 1.71B | 1.07B | 977.00M | 908.00M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Income - Net | -2.05B | -61.00M | -24.00M | -5.00M |
| Special Income / Charges | 0.00 | 0.00 | -36.00M | -684.00M |
| Total Income Before Interest Expenses (EBIT) | 2.13B | 3.05B | 3.85B | 2.40B |
| Interest Expense | 355.00M | 153.00M | 225.00M | 230.00M |
| Pre-Tax Income | 1.77B | 2.90B | 3.62B | 2.17B |
| Income Taxes | -137.00M | 127.00M | 283.00M | 166.00M |
| Minority Interest | -53.00M | 9.00M | 8.00M | 4.00M |
| Net Income From Continuing Operations | 1.91B | 2.76B | 3.33B | 2.00B |
| Net Income From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Total Operations | 1.91B | 2.76B | 3.33B | 2.00B |
| Extraordinary Income/Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Cum. Effect of Acct. Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Tax Loss Carryforward | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Net Income | 1.96B | 2.76B | 3.33B | 2.00B |
| Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge) |
1.91B | 3.66B | 3.76B | 2.66B |
| Preferred Dividends | ||||
|---|---|---|---|---|
| Net Income Available To Common | 1.91B | 2.76B | 3.33B | 2.00B |
| Basic EPS from Continuing Ops. | 2.25 | 3.10 | 3.72 | 2.29 |
| Basic EPS from Discontinued Ops. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Total Operations | 2.25 | 3.10 | 3.72 | 2.29 |
| Basic EPS from Extraordinary Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Tax Loss Carryf'd. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Other Gains (Losses) | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS, Total | 2.25 | 3.10 | 3.72 | 2.29 |
| Basic Normalized Net Income/Share | 2.25 | 4.11 | 4.20 | 3.05 |
| EPS fr Continuing Ops. | 2.25 | 3.09 | 3.67 | 2.23 |
| EPS fr Discontinued Ops | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Total Ops. | 2.25 | 3.09 | 3.67 | 2.23 |
| EPS fr Extraord. Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Tax Loss Carfd. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Other Gains (L) | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS, Total | 2.25 | 3.09 | 3.67 | 2.23 |
| Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge) |
2.25 | 4.10 | 4.14 | 2.97 |
| Dividends Paid per Share | 0.80 | 0.78 | 0.67 | 0.48 |
Portfolios with TEVA
- Portfolio NameUser Type
- UserDonnie Portfolio 2 High Grade
- UserMain
- UserLong Term Stock Picks
- UserTRIG
- Userfun and games
- Userabangser Portfolio 1
- ContributorHighest-Yielding Drug Stocks
- Contributor8 Pharma Stocks to Watch
- Userdividend
- UserIncome stocks
Latest TEVA Headlines from TheStreet
- 4 Stocks Improving Performance Of The Health Care Sector 05.16.13 | 01:05 pm
- 5 Stocks Going Ex-Dividend Tomorrow: LAND, RNDY, TROX, R, TEVA 05.15.13 | 10:05 am
- Teva Stock To Go Ex-dividend Tomorrow (TEVA) 05.15.13 | 09:05 am
- Teva Pharmaceutical Industries Ltd (TEVA): Today's Featured Health Care Winner 05.14.13 | 05:05 pm
- Teva Pharmaceutical Industries Ltd Stock Hold Recommendation Reiterated (TEVA) 05.10.13 | 10:05 am
- 'Mad Money' Lightning Round: Buy, Buy, Buy Biogen 05.10.13 | 06:05 am
- Cramer's 'Mad Money' Recap: Looking for Real Leaders 05.09.13 | 08:05 pm
- 5 Stocks Advancing The Drugs Industry 05.07.13 | 01:05 pm
- Teva Pharmaceutical Industries Ltd Stock Hold Recommendation Reiterated (TEVA) 04.29.13 | 10:04 am
- Teva Pharmaceutical Industries Ltd (TEVA): Today's Featured Drugs Winner 04.24.13 | 05:04 pm
Press Releases for TEVA
- Alexza Announces Conference Call To Discuss Agreement With Teva To Market ADASUVE® In The U.S. - PR Newswire 05.08.13 | 08:05 am
- Teva And Alexza Announce Teva's License To Market ADASUVE® In The U.S. - PR Newswire 05.08.13 | 08:05 am
- OncoGenex Announces Plans For The Initiation Of The Rainier⿢ Clinical Trial Evaluating OGX-427 In Combination With ABRAXANE® Plus Gemcitabine In Patients With Metastatic Pancreatic Cancer - PR Newswire 05.01.13 | 06:05 am
- OncoGenex Announces That The Borealis-2â¿¢ Clinical Trial Of OGX-427 In Previously Treated Metastatic Bladder Cancer Is Now Open For Enrollment - PR Newswire 04.30.13 | 08:04 am
- More Than Half Of Nasal Allergy Sufferers Experience Sleep Issues, Yet Many Fail To Adequately Prepare In Advance Of Peak Allergy Seasons - PR Newswire 04.23.13 | 08:04 am
- Apolo Anton Ohno And Teva Respiratory Announce Finalists In National EIB All Starsâ¿¢ Contest - PR Newswire 04.16.13 | 08:04 am
- OncoGenex Announces Plans For The Initiation Of The Spruceâ¿¢ Clinical Trial Evaluating OGX-427 In Combination With Chemotherapy In Advanced Non-Squamous Non-Small Cell Lung Cancer - PR Newswire 04.11.13 | 08:04 am
- Early Versus Delayed Treatment With Laquinimod Demonstrated Significant Reduction In Risk Of Disability Progression – Results Of Three-Year ALLEGRO Study In Relapsing-Remitting Multiple Sclerosis - Business Wire 03.21.13 | 08:03 am
- New Data Show Azilect® (rasagiline Tablets) Provided Clinical Benefit In Patients With Early Parkinson’s When Added To Sub-Optimally Controlled Patients On Dopamine Agonist Therapy - Business Wire 03.20.13 | 07:03 am
- Teva To Present New Research On CNS Product Portfolio And Pipeline At 2013 American Academy Of Neurology Annual Meeting - Business Wire 03.14.13 | 09:03 am
Partner Headlines for TEVA
- Analysts: SanDisk Will Beat Estimates and 4 New Opinions Investors Must Take Note Of - Wall St. Cheat Sheet 04.02.13 | 11:04 am
- 10 Sharp Healthcare Dogs Diagnose 7.4% To 62.1% Gains In March - Seeking Alpha 04.01.13 | 09:04 am
- FDA Approves NDA for Teva's Quartette Tablets to Prevent Pregnancy - Benzinga 03.29.13 | 11:03 am
- Brainstorm's Breakthrough ALS Clinical Data Shows The Promise In Stem Cell Therapy - Seeking Alpha 03.28.13 | 09:03 am
- Biogen MS Drug Approved; No 'Black Box' Label - Investor's Business Daily 03.27.13 | 06:03 pm
- Drug Companies Have Rebounded From The Patent Cliff With Acquisitions Now On The Mind - Seeking Alpha 03.25.13 | 09:03 am
- Valeant Earnings, Sales Top Estimates; Street Shrugs - Investor's Business Daily 02.28.13 | 05:02 pm
- 3 Industries Set To Profit From An Aging Population - Seeking Alpha 01.31.13 | 09:01 am
- Amgen Q4 Sales, 2013 Guidance Modestly Beat Estimates - Investor's Business Daily 01.23.13 | 06:01 pm
- Teva Pharmaceuticals - Food For Thought - Seeking Alpha 01.15.13 | 08:01 am
